TRAX (First Tracks Biotherapeutics) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2024)


TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $36.24
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics ROE % Adjusted to Book Value?

First Tracks Biotherapeutics TRAX +11.85% 12 ROE % Adjusted to Book Value is 0.00% as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

First Tracks Biotherapeutics's ROE % for the quarter that ended in Dec. 2024 was -40.85%. First Tracks Biotherapeutics's PB Ratio for the quarter that ended in Dec. 2024 was N/A. First Tracks Biotherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was N/A.

First Tracks Biotherapeutics ROE % Adjusted to Book Value Related Terms

First Tracks Biotherapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics ROE % Adjusted to Book Value Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
ROE % Adjusted to Book Value
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
ROE % Adjusted to Book Value 0.00 0.00

TRAX vs ALT, RGNX, MDXG: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, First Tracks Biotherapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

First Tracks Biotherapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where First Tracks Biotherapeutics's ROE % Adjusted to Book Value falls into.


TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics ROE % Adjusted to Book Value Calculation

First Tracks Biotherapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-40.85% / N/A
=N/A

First Tracks Biotherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-40.85% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
First Tracks Biotherapeutics (TRAX) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2024. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' ROE % Adjusted to Book Value too high?
First Tracks Biotherapeutics' current ROE % Adjusted to Book Value is 0.00%. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' ROE % Adjusted to Book Value compare to ALT and RGNX?
First Tracks Biotherapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.24
Price